Global Markets
Novartis CGTs first quarter 2022: Zolgensma up, Kymriah down
Therapeutic ClassNovartis CGTs first quarter 2022: Zolgensma up, Kymriah downNovartis CGTs first quarter 2022: Zolgensma up, Kymriah down
Novartis reports increased sales for gene therapy Zolgensma but the failure in the second-line DLBCL setting will affect Kymriah sales.